Related Experiment Video

Updated: Jun 28, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

The behavioral consequences of exposure to antiepileptic drugs in utero

J Vinten1, R L Bromley, J Taylor

  • 1Department of Clinical Psychology, Royal Liverpool Children's Hospital Alder Hey, Liverpool, UK.

Epilepsy & Behavior : E&B
|November 11, 2008
PubMed

Insights

Children exposed to sodium valproate (VPA) during pregnancy showed increased maladaptive behaviors and lower daily living and socialization skills. Full Scale IQ (FSIQ) influenced outcomes, but VPA exposure and lower FSIQ are identified risk factors.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pediatrics

Background:

  • Epilepsy in mothers can necessitate medication during pregnancy.
  • Sodium valproate (VPA) is a commonly prescribed antiepileptic drug.
  • Understanding prenatal VPA exposure effects on child development is crucial.

Purpose of the Study:

  • To investigate the behavioral outcomes in children exposed to sodium valproate (VPA) in utero.
  • To assess daily living skills and socialization in this cohort.
  • To explore the relationship between VPA exposure, Full Scale IQ (FSIQ), and behavioral development.

Main Methods:

  • Study included 242 children (aged 6-16) born to mothers with epilepsy.
  • Behavioral assessments focused on maladaptive behaviors, daily living skills, and socialization.
  • Statistical analysis considered the influence of child's Full Scale IQ (FSIQ).

Main Results:

  • Children exposed to VPA in utero exhibited higher levels of maladaptive behavior, leading to parental stress.
  • These children demonstrated poorer performance in daily living skills and socialization.
  • While Full Scale IQ (FSIQ) significantly impacted outcomes, it did not fully explain the observed differences.

Conclusions:

  • Prenatal exposure to sodium valproate (VPA) is associated with impaired adaptive behavior and increased maladaptive behaviors in children.
  • Lowered Full Scale IQ (FSIQ) and VPA exposure are identified as independent risk factors.
  • These findings highlight the need for careful consideration of VPA use during pregnancy and potential developmental monitoring.

More Related Videos

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...